Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2004-06-11
2011-12-06
Anderson, James D (Department: 1629)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S475000, C514S570000
Reexamination Certificate
active
08071645
ABSTRACT:
Systems and methods for treating inflammatory and proliferative diseases, and wounds, using as a pharmacon a fatty acid metabolism inhibitor, a glycolytic inhibitor, and/or an agent able to alter cellular production of reactive oxygen, or combination thereof, optionally in combination with one or more chemotherpeutic agents. In preferred embodiments, the invention combines an oxirane carboxylic acid, represented by etomoxir, with a 2-deoxyglucose compound, represented by 2-deoxy-D-glucose, and/or an antibody against UCP and/or Fas antigen. The systems and methods of the invention can be used to treat drug-resistant or multi-drug resistant cancers.
REFERENCES:
patent: 4935450 (1990-06-01), Cone, Jr.
patent: 5585363 (1996-12-01), Scanlon et al.
patent: 5587397 (1996-12-01), Fox
patent: 6331559 (2001-12-01), Bingham et al.
patent: 6569853 (2003-05-01), Borisy et al.
patent: 6582713 (2003-06-01), Newell et al.
patent: 6670330 (2003-12-01), Lampidis
patent: 6846816 (2005-01-01), Borisy et al.
patent: 6951887 (2005-10-01), Bingham et al.
patent: 7160865 (2007-01-01), Lampidis et al.
patent: 7390782 (2008-06-01), Newell
patent: 7510710 (2009-03-01), Newell et al.
patent: 2002/0107234 (2002-08-01), Bingham et al.
patent: 2003/0212138 (2003-11-01), Obukowicz
patent: 2005/0020682 (2005-01-01), Newell et al.
patent: 2005/0074882 (2005-04-01), Newell
patent: 2005/0158333 (2005-07-01), Newell et al.
patent: 2005/0202559 (2005-09-01), Pownall et al.
patent: 2006/0140953 (2006-06-01), Newell et al.
patent: 2006/0247199 (2006-11-01), Newell et al.
patent: 0 239 400 (1987-09-01), None
patent: WO 95/19765 (1995-07-01), None
patent: WO 01/34145 (2001-05-01), None
patent: WO 03/037323 (2003-05-01), None
patent: WO 2006/042062 (2006-04-01), None
patent: WO 2006/108276 (2006-10-01), None
Sausville et al. Contributions of human tumor xenografts to anticancer drug development. Cancer Research, 2006, vol. 66, pp. 3351-3354.
Johnson et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. British J. of Cancer, 2001, 84(10):1424-1431.
Tao et al. Effect of dichloroacetic acid and trichloroacetic acid on DNA methylation in liver and tumors of female B6C3F1 mice. Toxicological Sciences, 1998, vol. 43, No. 2, pp. 139-144.
Harrington-Broack et al. Mutagenicity of three disinfection by-products: di- and trichloroacetic acid and chloral hydrate in L5178Y/TK +/− (−)3.7.2c mouse lymphoma cells. Mutation Research, 1998, vol. 413, No. 3, pp. 265-276.
Durig et al. Ann. Hematol., 1996, vol. 72, pp. 97-99.
Kaplan et al. Cancer Res., 1990, vol. 50, pp. 544-551.
Kubota et al. Ann. Oncol., 2000, vol. 11, pp. 445-450.
Lissoni et al. Anticancer Res., 2002, vol. 22, pp. 1061-1064.
Stanley et al. J. Mol. Cell Cardiol., 1996, vol. 28, pp. 905-914.
Saddick et al. The Journal of Biological Chemistry, 1993, vol. 268, No. 34, pp. 25836-25845.
Page et al. Principles of Chemotherapy, Cancer Management: A Multidisciplinary Approach, 7th Ed., 2003, pp. 21-37.
Database CAPLUS on STN (Columbus, OH, USA) DN 135:313274, Thupari H et al., “Fatty acid synthase inhibition in human breast cancel cells leads to malonyl-CoA-induced inhibition of fatty acid oxidation and cytotoxicity,” Bioblem & Biophysical Res Com, 2001, vol. 285, No. 2, pp. 217-223, abstract.
Database CAPLUS on STN (Columbus, OH, USA) DN 135:348254, Pizer E et al., “Treating cancer by increasing intracellular malonyl CoA levels” W02001034145, May 17, 2001.
Database MEDLINE on STN (Columbus, OH, USA) AN 90008014, Saydjari R et al., “2-deixt-D-glucose inhibits the antitumor effects of alpha-difluoromethylornithine on the growth of colon cancer in vivo,” Investigational new drugs, Jul. 1989, vol. 7, No. 2-3, pp. 131-138, abstract.
Clement et al., EMBO J. Jan. 15, 1996; 15(2):216-225.
Li et al, Endocrinology. Apr. 2002, 143(4): 1371-1377.
Kuhajda et al, PNAS USA, Mar. 28, 2000; 97(7) 3450-3454: Epub Mar. 14, 2000.
Black et al., Cancer Res. May 1, 1949; 9:314-319; Abstract Only.
Alberts et al., Molecular Biology of the Cell. 4thEd. Garland Science, 2002, NY at p. 856-857, Fig. 15-32.
Calkins et al., UNL Beef Cattle Reports. Univ. of Nebraska Cooperative Extension-MP71. Beef. Feb. 1999.
Strieleman et al., J.Biol. Chem. Nov. 5, 1985, 260(25):13402-13405.
Cabrero et al, Biochemica et al Biophysica Acta. 2001; 1532:195-202 Abstract.
Constantini et al. J of Nat'l Cancer Inst., v.92, p. 1042 (2000).
Fantin et al, Cancer Cell, v. 2 p. 29.(2002).
Bull et al., Environ. Health Persp. V.108, p. 241 (2000).
Stacpoole et al., Controlled Clinical Trail of Dichloroacetate for Treatment of Congenital Lactic Acidosis in Children, Pediatrics, 117(5): 1519-1532, May 2006.
Stacpoole et al., Clinical Pharmacology and Toxicology of Dichloroacetate, Environmental Health Perspectives, 106(4): 989-994, Aug. 1998.
Stacpoole et al., Treatment of congenital lactic acidosis with dichloroacetate, Archives of Disease in Childhood, 77:535-541, 1997.
Baggetto, “Deviant energetic metabolism of glycolytic cancer cells,” Biochimie. Nov; 74(11):959-74 (1992).
Bitar, “Co-Administration of Etomoxir and RU-486 Mitigates Insulin Resistance in Hepatic and Muscular Tissues of STZ-Induced Diabetic Rats,” Hormone and Metabolic Research, vol. 33(10) Jan. 1 p. 577-584 (2001).
Black et al., “Glycolytic enzyme inhibitor therapy in human malignant neoplasia,” Cancer Res. May 1; 9:314-319 (1949).
Dang et al., “Oncogenic alterations of metabolism,” Trends Biochem. Sci. Feb; 24(2): 68-72 (1999).
Fanciulli et al. “Effect of the antitumor drug lonidamine on glucose metabolism of adriamycin-sensitive and—resistant human breast cancer cells,” Oncology Res. 8(3): 111-120 (1996).
Healy et al., “Glucose, but not glutamine, protects against spontaneous and anti-Fas antibody0induced apoptosis in human neutrophils,” Clinical Science, Aug. 2002; 103:179-189.
Newell et al., “Does the oxidative/glycolytic ratio determine proliferation or death in immune recognition,” Ann NY Acad Sci, 887:77-82 (1999).
Newell et al, “The effects of chemotherapeutics on cellular metabolism and consequent immune recognition,” J Immune Based Ther Vaccines, Feb. 2; 2(1):3 (2004).
Newell et al,, “Studies with glycolysis-deficient cells suggest that production of lactic acid is not the only cause of tumor acidity,” PNAS; vol. 90; pp. 1127-1131 (1993).
Satoh et al., “Changes in mitochondrial membrane potential during oxidative stress-induced apoptosis in PC12 cells,” J. Neurosci Res, Nov 1; 50(3): 413-20 (1997).
Saydjari et al., “2-Deoxy-D-glucose inhibits the antitumor effects of alpha-difluoromethylornithine on the growth of colon cancer in vivo,” Invest New Drugs Jul; 7(2-3): 131-8 (1989).
Shoukry and Schulz, “Significance of the Reductase-dependent Pathway for the β-Oxidation of Unsaturated Fatty Acids with Odd-numbered Double Bonds,” J. Biol. Chem 273(12) 1998; 6892-6899.
Tschimelitsch et al, “Enhanced Antitumor Activity of Combination Radioimmunotherapy . . .”Canc. Res. Jun 1, 1997; 57(11):2181-6; Abstract Only.
Thupari et al., “Fatty acid synthase inhibition in human breast cancer cells leads to malonyl-CoA-induced inhibition of fatty acid oxidation and cytotoxicity,” Biochem Biophys Res Commun Jul 13; 285(2):217-23 (2001) Erratum in: Biochem Biophys Res Commun Jul. 12; 295(2): 570 (2002).
Stacpoole et al., “Clinical Pharmacology and Toxicology of Dichloroacetate”Environmental Health Perspectives, vol. 106, Supplement 4, Aug. 1998.
Blask et al., Melatonin inhibition of cancer growth in vivo involves suppression of tumor fatty acid metabolism via melatonin receptor-mediated signal transduction events. Cancer Res. Sep. 15, 1999;59(18):4693-701.
Visonneau et al., Conjugated linoleic acid suppresses the growth of human breast adenocarcinoma cells in SCID mice. Anticancer Res. Mar.-Apr. 1997;17(2A):969-73.
Newell Evan
Newell M. Karen
Villalobos-Menuey Elizabeth
Anderson James D
The Regents of the University of Colorado
Wolf Greenfield & Sacks P.C.
LandOfFree
Systems and methods for treating human inflammatory and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Systems and methods for treating human inflammatory and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Systems and methods for treating human inflammatory and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4310667